# CKD-841 Pharmacokinetic/Pharmacodynamic Study

> **NCT03233932** · PHASE1 · COMPLETED · sponsor: **Chong Kun Dang Pharmaceutical** · enrollment: 13 (actual)

## Conditions studied

- Postmenopausal Disorder

## Interventions

- **DRUG:** LeuplinⓡInj
- **DRUG:** CKD-841

## Key facts

- **NCT ID:** NCT03233932
- **Lead sponsor:** Chong Kun Dang Pharmaceutical
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-04
- **Primary completion:** 2017-07
- **Final completion:** 2017-07
- **Target enrollment:** 13 (ACTUAL)
- **Last updated:** 2017-07-31

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03233932

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03233932, "CKD-841 Pharmacokinetic/Pharmacodynamic Study". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT03233932. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*